Dianthus Therapeutics’ (DNTH) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Monday morning,Benzinga reports. Wedbush currently has a $46.00 price objective on the stock.

A number of other analysts have also commented on DNTH. Truist Financial initiated coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price target for the company. HC Wainwright raised their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Raymond James Financial reaffirmed an “outperform” rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim raised their price target on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.43.

Dianthus Therapeutics Price Performance

DNTH stock opened at $43.16 on Monday. The stock has a market capitalization of $1.85 billion, a P/E ratio of -12.40 and a beta of 1.56. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $45.46. The business has a fifty day moving average price of $39.39 and a 200-day moving average price of $30.25.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.58 million. As a group, analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $152,560. The trade was a 96.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 216,538 shares of company stock worth $8,283,175 over the last quarter. Insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Parkside Financial Bank & Trust lifted its position in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after buying an additional 540 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in Dianthus Therapeutics by 3.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock worth $332,000 after acquiring an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Dianthus Therapeutics by 0.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock valued at $3,049,000 after purchasing an additional 1,081 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Dianthus Therapeutics by 7.8% in the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock worth $635,000 after purchasing an additional 1,170 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.